T&R Biofab Obtains Domestic Patent for 'Cardiomyocyte Aggregate Fabrication Technology'

[Asia Economy Reporter Kum Boryeong] T&R Biofab has obtained a patent for heart tissue regeneration technology using induced pluripotent stem cells.

On the 2nd, T&R Biofab announced that it acquired a domestic patent related to the "technology for producing myocardial cell aggregates that improve survival rates under cryopreservation and hypoxic conditions."

This patent pertains to technology that uniformly produces myocardial cells in a 3-dimensional structure of 100 μm. The therapeutic efficacy of improving damaged heart function by increasing the in vivo survival rate of the cells was verified through a myocardial infarction animal model.

The produced myocardial cell aggregates can be cryopreserved for more than six months. This advantage allows immediate use for patients with sudden heart diseases. It can also be applied as a cell therapy technology that lowers patient burden by transplanting cells through catheter procedures without open-heart surgery.

Yoon Wonsoo, CEO of T&R Biofab, stated, "We plan to apply for an Investigational New Drug (IND) application after non-clinical safety evaluation using our self-developed iPSC cell line for this patented technology," adding, "Since the patent scope includes myocardial cell production technology and target diseases, we will review multifaceted commercialization strategies such as technology transfer with global companies developing cell therapies for related diseases."

This content was produced with the assistance of AI translation services.